… Definite or probable ketoacidosis occurred in 2 patients without heart failure randomly
allocated to placebo; there were no cases of ketoacidosis in the dapagliflozin group. …

… (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction
Heart Failure) … from long-term use of dapagliflozin in patients with HF with mildly reduced or …

… the effect of dapagliflozin on patients with heart failure, we … mortality, and heart failure-related
hospitalization. Additionally, … and urgent heart failure visits were observed with dapagliflozin …

… or worsening heart failure when dapagliflozin was initiated in patients with heart failure with
… large absolute risk reductions in patients with a more recent heart failure hospitalization. …

… patients with heart failure and a left ventricular ejection fraction of more than 40% to receive
dapagliflozin (… The primary outcome was a composite of worsening heart failure (which was …

… Failure), the SGLT2 inhibitor dapagliflozin reduced the incidence of the primary composite
outcome of cardiovascular death or worsening heart failure (HF) in patients … of dapagliflozin …

… Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of …
patients with HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor dapagliflozin …

… Obesity is common in patients with HFpEF and is associated with higher rates of heart
failure hospitalization and worse health status. Treatment with dapagliflozin improves …

… Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of
worsening heart failure and death in patients with heart failure and reduced ejection fraction. We …

… In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening
heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined …